Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

Irfan Vardarli; Michael A. Nauck; Lars D. K?the; Carolyn F. Deacon; Jens J. Holst; Anja Schweizer; James E. Foley

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

【24h】

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

机译：抑制DPP-4与Vilyagliptin改善了口服以及“异糖性”静脉内葡萄糖的胰岛素分泌，而不会数值改变2型糖尿病患者的增量素效应

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Aims:Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.

机译：背景和目的：二肽基肽酶-4（DPP-4）抑制剂阻断胰高血糖素肽-1和葡萄糖依赖性胰岛素渗透多肽的降解。本研究的目的是定量评估用2型糖尿病患者用DPP-4抑制剂Vildagliptin（V）或安慰剂（P）治疗后的增量素效应。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2011年第4期|共10页
作者
Irfan Vardarli; Michael A. Nauck; Lars D. K?the; Carolyn F. Deacon; Jens J. Holst; Anja Schweizer; James E. Foley;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and 'Isoglycemic' Intravenous Glucose [J] . Irfan Vardarli, Elisabeth Arndt, Carolyn F. Deacon, Diabetes . 2014,第2期

机译：西他列汀和二甲双胍对口服和“等血糖”静脉葡萄糖对肠促胰岛素激素和胰岛素分泌反应的影响
2. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. [J] . Hare KJ, Vilsboll T, Holst JJ, American Journal of Physiology . 2010,第4aPta1期

机译：与1型糖尿病患者的异血静脉葡萄糖给药相比，在口服胰腺癌后反应。
3. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. [J] . Hare KJ, Vilsboll T, Holst JJ, American Journal of Physiology . 2010,第4aPta1期

机译：与1型糖尿病患者等剂量静脉注射葡萄糖相比，口服后胰高血糖素反应不当。
4. Incretin-Induced Insulin Potentiation Characterized by an Improved Mathematical Model of Oral Glucose Tolerance Test [C] . M. Morettini, G. Guercio, R. Burattini European Conference of the International Federation for Medical and Biological Engineering . 2013

机译：Incetin诱导的胰岛素增强，其特征在于口服葡萄糖耐量测试的改进数学模型
5. The relationship between the emotional burden of Type 2 Diabetes and glycemic control and differences in emotional burden and glycemic control among individuals treated with oral antidiabetic agents, combination therapy, incretin mimetic, and insulin [D] . Douaihy, Katharine 2008

机译：2型糖尿病患者的情绪负担与血糖控制之间的关系以及口服抗糖尿病药，联合疗法，降钙素模拟物和胰岛素治疗的个体之间情绪负担和血糖控制的差异
6. Preserved glucagon-like peptide-1 responses to oral glucose but reduced incretin effect insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus [O] . Toh Peng Yeow, Giovanni Pacini, Andrea Tura, 2017

机译：保留胰高血糖素样肽1对口服葡萄糖的反应但在年轻的2型糖尿病亚洲人中肠降血糖素作用胰岛素分泌和敏感性降低
7. Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes [O] . Irfan Vardarli, Michael A. Nauck, Lars D. Köthe, 2011

机译：抑制DPP-4与Vilyagliptin改善了口服以及“异糖性”静脉内葡萄糖的胰岛素分泌，而不会数值改变2型糖尿病患者的增量素效应

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

摘要

著录项

相似文献

相关主题

期刊订阅